White Paper

Practical Strategies For Ensuring A Diverse Patient Population In Clinical Trials

Source: Citeline
Diversity-GettyImages-1406072634

The FDA's 2025 initiative to improve patient recruitment in clinical trials by mandating Diversity Action Plans (DAPs), aims to address how medications affect diverse populations by enhancing the participation of underrepresented communities. The FDA's guidance, expected by June 2025, will require companies to set and monitor enrollment goals based on ethnicity, race, sex, and age, employing strategies like community engagement and flexible study hours.

Recruitment challenges can be exacerbated by complex protocols and a shortage of experienced professionals post-COVID. Companies are leveraging grassroots outreach and technology, including AI, to identify participants. Regulatory changes will enforce diversity across all trials, prompting companies to prioritize inclusive strategies. Decentralized trials and strategic site selection are suggested to overcome participation barriers. The FDA's guidance is seen as a positive step, despite potentially slowing recruitment, encouraging the industry to rethink strategies to ensure equitable access to clinical trials and treatments for all individuals.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader